AG
EDIT icon

Algert Global’s Editas Medicine EDIT Stock Holding History

Algert Global’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-54,510
Closed -$404K – 1522
2024
Q1 		$404K Buy
+54,510
New +$453K 0.02% 822
2022
Q3 		– Sell
-10,285
Closed -$122K – 1211
2022
Q2 		$122K Sell
10,285
-1,550
-13% -$20.8K 0.01% 1092
2022
Q1 		$225K Buy
+11,835
New +$220K 0.01% 1021
2021
Q4 		– Sell
-5,463
Closed -$224K – 1004
2021
Q3 		$224K Buy
+5,463
New +$299K 0.03% 865

Other funds holding EDIT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Algert Global's EDIT Position: Q2 2024 in Review

Algert Global sold out of Editas Medicine (EDIT) in Q2 2024, closing a stake of 54,510 shares — an estimated $404K sold.

Algert Global first reported a position in EDIT in Q3 2021 and held it in 4 quarters. The position peaked at $404K in Q1 2024. 235 funds tracked by Wall St. Rank hold EDIT as of Q2 2024.

  • Algert Global reported no remaining Editas Medicine position as of Q2 2024 after selling out during the quarter.
  • Algert Global sold 54,510 Editas Medicine shares in Q2 2024, an estimated $404K.
  • Algert Global first reported a position in Editas Medicine in Q3 2021 and held it in 4 quarters.
  • Algert Global's Editas Medicine position peaked at $404K in Q1 2024.
  • 235 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2024.

Based on Algert Global's 13F filing for Q2 2024, filed 15 Aug 2024.